{"blog": [], "keywords": [{"value": "Gluten", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Celiac Disease", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "4", "is_major": "Y"}, {"value": "AbbVie Inc", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "GlaxoSmithKline PLC", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Avalon Ventures Limited", "name": "organizations", "rank": "7", "is_major": "N"}, {"value": "Alvine Pharmaceuticals Inc", "name": "organizations", "rank": "8", "is_major": "N"}, {"value": "Sitari Pharmaceuticals Inc", "name": "organizations", "rank": "9", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/04/29/business/celiac-diseases-prominence-has-drug-companies-racing-to-find-treatments.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbWide.jpg", "legacy": {"wide": "images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/04/28/business/29gluten-web1/29gluten-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/28/business/29gluten-web1/29gluten-web1-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/04/28/business/29gluten-web1/29gluten-web1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1426", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "It&#8217;s estimated that about three million Americans have celiac disease. And even though a gluten-free diet can help alleviate symptoms, it&#8217;s not a cure-all.", "pub_date": "2015-04-29T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Treating Celiac Disease", "main": "As Celiac and Gluten Sensitivities Gain Prominence, Drug Companies Race to Find Treatments"}, "print_page": "1", "snippet": "It&#8217;s estimated that about three million Americans have celiac disease. And even though a gluten-free diet can help alleviate symptoms, it&#8217;s not a cure-all.", "_id": "553ff2f438f0d877377da0eb", "slideshow_credits": null, "abstract": "Pharmaceuticals are racing to develop first drugs for celiac disease, condition that is now understood to be far more common than previously thought; drugs, which will not reach market until at least 2018, would not eliminate need for gluten-free diet, but could alleviate symptoms from trace elements; Food and Drug Admin is moving to develop standards for measuring drugs' effectiveness."}